Artículos por temáticas

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease

Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R.

JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937.

The regulation of miRNAs using curcumin and other polyphenols during the prevention and treatment of Alzheimer's disease

Wang X, Zhang S, Li Y, Zhang Y.

Hum Mol Genet. 2025 Jan 29;34(2):117-127. doi: 10.1093/hmg/ddae154.

From data to discovery: Neuroinformatics in understanding Alzheimer's disease

Pahal S, Pahal V, Chaudhary A.

J Biosci. 2025;50:2.

Alzheimer's Disease: Exploring Pathophysiological Hypotheses and the Role of Machine Learning in Drug Discovery

Dominguez-Gortaire J, Ruiz A, Porto-Pazos AB, Rodriguez-Yanez S, Cedron F.

Int J Mol Sci. 2025 Jan 24;26(3):1004. doi: 10.3390/ijms26031004.

The Role of Oligodendrocyte Lineage Cells in the Pathogenesis of Alzheimer's Disease

Liu X, Lv Z, Huang Q, Lei Y, Liu H, Xu P.

Neurochem Res. 2025 Jan 3;50(1):72. doi: 10.1007/s11064-024-04325-3.

Senescent microglia: The hidden culprits accelerating Alzheimer's disease

Li W, Yong-Yan X, Jia-Xin M, Shu-Chao G, Li-Ping H.

Brain Res. 2025 Mar 15;1851:149480. doi: 10.1016/j.brainres.2025.149480. Epub 2025 Jan 28.

Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy

Ahn EH, Park JB.

Cells. 2025 Jan 10;14(2):89. doi: 10.3390/cells14020089.

Role of tau versus TDP-43 pathology on medial temporal lobe atrophy in aging and Alzheimer's disease

Wisse LEM, Wuestefeld A, Murray ME, Jagust W, La Joie R.

Alzheimers Dement. 2025 Feb;21(2):e14582. doi: 10.1002/alz.14582.

Extracellular vesicle-packed microRNAs profiling in Alzheimer's disease: The molecular intermediary between pathology and diagnosis

Arif S, Qazi TJ, Quan Z, Ni J, Li Z, Qiu Y, Qing H.

Ageing Res Rev. 2025 Feb;104:102614. doi: 10.1016/j.arr.2024.102614. Epub 2024 Dec 1.

Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies

Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J.

Front Immunol. 2025 Jan 14;15:1484373. doi: 10.3389/fimmu.2024.1484373. eCollection 2024.

Non-coding RNAs in the pathogenesis of Alzheimer's disease: β-amyloid aggregation, Tau phosphorylation and neuroinflammation

Jiménez-Ramírez IA, Castaño E.

Mol Biol Rep. 2025 Jan 31;52(1):183. doi: 10.1007/s11033-025-10284-x.

Cell-specific transcriptional signatures of vascular cells in Alzheimer's disease: perspectives, pathways, and therapeutic directions

Chaudhuri S, Cho M, Stumpff JC, Bice PJ, İş Ö, Ertekin-Taner N, Saykin AJ, Nho K.

Mol Neurodegener. 2025 Jan 29;20(1):12. doi: 10.1186/s13024-025-00798-0.

Neuroimaging Findings of Psychosis in Alzheimer's Disease: A Systematic Review

Nabizadeh F, Sheykhlou S, Mahmoodi S, Khalili E, Zafari R, Hosseini H.

Brain Behav. 2025 Jan;15(1):e70205. doi: 10.1002/brb3.70205.

Neural mechanisms of non-pharmacological interventions in patients with mild cognitive impairment and Alzheimer's disease: An ALE meta-analysis

Wang N, Li J, Guo Y, Zhang P, You F, Wang Z, Wang Z, Hong X.

Exp Gerontol. 2025 Feb;200:112678. doi: 10.1016/j.exger.2025.112678. Epub 2025 Jan 9.

Massive changes in gene expression and their cause(s) can be a unifying principle in the pathobiology of Alzheimer's disease

Coleman PD, Delvaux E, Kordower JH, Boehringer A, Huseby CJ.

Alzheimers Dement. 2025 Feb;21(2):e14555. doi: 10.1002/alz.14555. Epub 2025 Feb 6.